UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000038441
Receipt number R000043798
Scientific Title Plasma concentration and urinary excretion of SNR14 in healthy male volunteers after single oral administration of foods containing SNR14
Date of disclosure of the study information 2019/11/01
Last modified on 2020/10/15 14:53:52

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Plasma concentration and urinary excretion of SNR14 in healthy male volunteers after single oral administration of foods containing SNR14

Acronym

Absorption study of SNR14

Scientific Title

Plasma concentration and urinary excretion of SNR14 in healthy male volunteers after single oral administration of foods containing SNR14

Scientific Title:Acronym

Absorption study of SNR14

Region

Japan


Condition

Condition

Healthy Volunteer

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To examine the absorption of SNR14 after single oral administration of foods containing SNR14

Basic objectives2

Pharmacokinetics

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Plasma concentration of SNR14 after single oral administration

Key secondary outcomes

Urinary excretion of SNR14 after single oral administration


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Dose comparison

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

3

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Single oral administration of SNR14 A

Interventions/Control_2

Single oral administration of SNR14 B

Interventions/Control_3

Single oral administration of SNR14 C

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

60 years-old >=

Gender

Male

Key inclusion criteria

1)Subjects who are voluntarily giving written informed consent.
2)Healthy males aged between 20 and 60.
3)Subjects who can eat test foods.
4)Subjects who can take meals, eat test foods, take blood samples, take urine samples and stay quiet and rest on the schedule indicated by investigators.

Key exclusion criteria

1)Subjects whose clinical inspection results are outside of the normal range and who are estimated inappropriate to this study.
2)Subjects who have or had disorder in digestive, circulatory or endocrine system and who are estimated inappropriate to this study.
3)Subjects who take medicines for treatment of diseases.
4)Subjects who have allergy.
5)Subjects who are estimated inappropriate to this study by principal investigator or investigators.

Target sample size

12


Research contact person

Name of lead principal investigator

1st name Yasutaka
Middle name
Last name Ikeda

Organization

Otsuka Pharmaceutical Co., Ltd.

Division name

Saga Nutraceuticals Research Institute

Zip code

842-0195

Address

5006-5 Aza Higashiyama, Omagari, Yoshinogari-cho Kanzakigun, Saga

TEL

0952-52-1522

Email

Ikeda.Yasutaka@otsuka.jp


Public contact

Name of contact person

1st name Minoru
Middle name
Last name Akiyama

Organization

Otsuka Pharmaceutical Co., Ltd.

Division name

Saga Nutraceuticals Research Institute

Zip code

842-0195

Address

5006-5 Aza Higashiyama, Omagari, Yoshinogari-cho Kanzakigun, Saga

TEL

0952-52-1522

Homepage URL


Email

Akiyama.Minoru@otsuka.jp


Sponsor or person

Institute

Otsuka Pharmaceutical Co., Ltd.

Institute

Department

Personal name



Funding Source

Organization

Otsuka Pharmaceutical Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Otsuka Pharmaceutical Co., Ltd.

Address

Shinagawa Grand Central Tower, 2-16-4, Konan, Minato-ku, Tokyo

Tel

03-6717-1499

Email

shimizu_se@otsuka.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 11 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 10 Month 09 Day

Date of IRB

2019 Year 10 Month 09 Day

Anticipated trial start date

2019 Year 10 Month 15 Day

Last follow-up date

2019 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2019 Year 10 Month 30 Day

Last modified on

2020 Year 10 Month 15 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043798


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name